Biodexa Pharmaceuticals shares surge following phase 2 trial results for eRapa, a potential treatment for Familial Adenomatous Polyposis. The study showed a 17% median reduction in polyp burden and a 75% non-progression rate. Phase 3 trial preparations underway.
Read more